Deals this week: Milestone Pharmaceuticals, Homology Medicines, Ultragenyx Pharmaceutical
Canadian cardiovascular drug development company Milestone Pharmaceuticals has secured $55m through a series C funding round led by Novo Holdings.
The company plans to use the funds to progress the development of its lead product etripamil into Phase 3. The funds will also be used towards marketing and increasing headcount.
Homology Medicines has secured $83.5m through a series B funding round led by Deerfield Management Company.
The US-based genetic medicines company plans to use the funds to advance the development of its lead candidate AMEnDR™, which is currently in the pre-clinical stage.
Ultragenyx Pharmaceutical plans to issue common stock shares through a public offering to raise up to $150m.
The US-based clinical-stage biopharmaceutical company plans to use the funds to advance the development of its clinical and pre-clinical products as well as towards working capital and general corporate purposes.
PreciThera has secured C$36m ($28.8m) through a financing round led by Arix Bioscience.
Based in Canada, PreciThera is a biotechnology company focused on the development of orphan bone diseases. The company plans to use the funds to progress its drug candidates into the clinical stage.